A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

124

Participants

Timeline

Start Date

September 27, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

SHR-A2102

SHR-A2102: injection, 80mg/ bottle, intravenous drip

DRUG

Adebelimab (SHR-1316)

Adebelimab (SHR-1316): injection, 600mg(12mL)/ bottle, intravenous drip

DRUG

SHR-8068

SHR-8068: injection, 50mg（10mL）/ bottle, intravenous drip

Trial Locations (1)

RECRUITING

Shanghai Chest Hospital, Shanghai

All Listed Sponsors

lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY